Elliott Takes Aim at Bio-Rad: Activist Investor Pushes for Turnaround
Elliott bought into Bio-Rad to boost its weak stock, betting on turnaround and its valuable Sartorius stake driving future growth.
/ 2 items
Elliott bought into Bio-Rad to boost its weak stock, betting on turnaround and its valuable Sartorius stake driving future growth.
Citi downgrades Bio-Rad to Neutral, citing weak chromatography growth and China market risks; price target cut to $300.